M118104

M118104 is an investigational topical pharmaceutical agent being developed by Maruho Co., Ltd. for the treatment of dermatological conditions involving skin barrier dysfunction, specifically sebum deficiency and progressive palmar keratoderma. Sebum deficiency (xerosis) is characterized by a lack of skin surface lipids, leading to dryness, irritation, and a compromised epidermal barrier. Progressive palmar keratoderma is a chronic inflammatory condition of the hands that results in hyperkeratosis, scaling, and painful fissuring. M118104 is currently in Phase 2 clinical development in Japan, where it is being evaluated for its ability to restore skin hydration and improve clinical symptoms in patients with these conditions. As a non-steroidal topical treatment, it aims to provide a safe and effective alternative for long-term management of chronic skin barrier disorders.